{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:54:50Z","timestamp":1787320490087,"version":"build-2736575974"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic central nervous system disease characterized by neurodegeneration and inflammation. Neurofilament light chain (NfL), a protein released during axonal injury, has gained recognition as a potential biomarker for monitoring MS progression and treatment response. Evidence indicates that blood NfL (bNfL) offers a minimally invasive, cost-effective tool for tracking neuroaxonal damage. Regular bNfL assessments can identify subclinical disease activity, guide treatment intensification, and support individualized care. However, bNfL level evaluation is currently not optimized in Italian clinical practice. This work examines the utility of bNfL monitoring in clinical practice, focusing on optimizing its use within specific patient profiles, especially in resource-limited settings. bNfL testing, particularly in targeted MS patient profiles, including stable patients exhibiting subclinical signs of disease activity, such as fatigue, and patients off-treatment, represents a promising adjunct for personalized disease management. Its integration into clinical practice, alongside MRI and clinical assessments, can enhance decision-making and improve care efficiency, especially in settings with limited MRI resources. Further research is needed to standardize testing protocols and establish disease-specific cutoffs.<\/jats:p>","DOI":"10.3389\/fneur.2025.1571605","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T11:54:36Z","timestamp":1743162876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Diego","family":"Centonze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/cimb45020094","article-title":"Multiple sclerosis: inflammatory and Neuroglial aspects","volume":"45","author":"Papiri","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1242\/jcs.104729","article-title":"Neurofilaments at a glance","volume":"125","author":"Yuan","year":"2012","journal-title":"J Cell Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1034684","DOI":"10.3389\/fnagi.2022.1034684","article-title":"Neurofilaments contribution in clinic: state of the art","volume":"14","author":"Delaby","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum Neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at Subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"ref8","author":"Kuhle","year":"2018"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the Neurofilament light chain in blood samples: Elisa, Electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum Neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association between serum Neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years","volume":"76","author":"Canto","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum Neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma Neurofilament light chain levels in patients with Ms switching from injectable therapies to Fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult Scler"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"105748","DOI":"10.1016\/j.msard.2024.105748","article-title":"Prevalence of elevated Snfl in a real-world setting: results on 908 patients with different multiple sclerosis types and treatment conditions","volume":"88","author":"Bava","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e1130","DOI":"10.1212\/NXI.0000000000001130","article-title":"Assessing Neurofilaments as biomarkers of neuroprotection in progressive multiple sclerosis: from the Ms-stat randomized controlled trial","volume":"9","author":"Williams","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-022-00427-8","article-title":"Serum Neurofilament light trajectories and their relation to subclinical radiological disease activity in relapsing multiple sclerosis patients in the Aplios trial","volume":"12","author":"Bar-Or","year":"2023","journal-title":"Neurol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"852563","DOI":"10.3389\/fimmu.2022.852563","article-title":"Prognostic value of serum Neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 Asclepios I and II trials","volume":"13","author":"Ziemssen","year":"2022","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood Neurofilament light levels predict non-relapsing progression following anti-Cd20 therapy in relapsing and primary progressive multiple sclerosis: findings from the Ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/ijms24044067","article-title":"Serum Neurofilament light chain as biomarker for Cladribine-treated multiple sclerosis patients in a real-world setting","volume":"24","author":"Seiberl","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum Neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/1352458520912379","article-title":"Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis","volume":"27","author":"Uher","year":"2021","journal-title":"Mult Scler"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1177\/1352458518775303","article-title":"High Neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome","volume":"25","author":"Van Der Vuurst De Vries","year":"2019","journal-title":"Mult Scler"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1352458519901272","article-title":"Serum Neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis","volume":"27","author":"Srpova","year":"2021","journal-title":"Mult Scler"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e2120","DOI":"10.1212\/WNL.0000000000200258","article-title":"Blood Neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials","volume":"98","author":"Leppert","year":"2022","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1007\/s00415-023-11841-9","article-title":"Serum levels of Neurofilament light chains in pediatric multiple sclerosis: a systematic review and Meta-analysis","volume":"270","author":"Niculae","year":"2023","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/13524585221144742","article-title":"Plasma Neurofilament light chain in children with relapsing Ms receiving Teriflunomide or placebo: a post hoc analysis of the randomized Terikids trial","volume":"29","author":"Kuhle","year":"2023","journal-title":"Mult Scler"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10072-023-07228-3","article-title":"Current use of fluid biomarkers as outcome measures in multiple sclerosis (Ms): a review of ongoing pharmacological clinical trials","volume":"45","author":"Schilke","year":"2024","journal-title":"Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of Neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"ref30","first-page":"1","year":"2021"},{"key":"ref31","year":"2024"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"102807","DOI":"10.1016\/j.ebiom.2020.102807","article-title":"Clinical implications of serum Neurofilament in newly diagnosed Ms patients: a longitudinal multicentre cohort study","volume":"56","author":"Bittner","year":"2020","journal-title":"EBioMedicine"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1177\/1352458519882279","article-title":"Serum Neurofilament levels correlate with retinal nerve Fiber layer thinning in multiple sclerosis","volume":"26","author":"Bsteh","year":"2020","journal-title":"Mult Scler"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.1212\/NXI.0000000000001051","article-title":"Increased serum Neurofilament light and thin ganglion cell-inner plexiform layer are additive risk factors for disease activity in early multiple sclerosis","volume":"8","author":"Lin","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/biomedicines11020606","article-title":"Serum Neurofilaments and Oct metrics predict Edss-plus score progression in early relapse-remitting multiple sclerosis","volume":"11","author":"Tiu","year":"2023","journal-title":"Biomedicines"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2147588","DOI":"10.1001\/jamanetworkopen.2021.47588","article-title":"Serum Neurofilament light and multiple sclerosis progression independent of acute inflammation","volume":"5","author":"Gafson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1007\/s00415-024-12701-w","article-title":"In multiple sclerosis patients a single serum Neurofilament light chain (Snfl) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting","volume":"271","author":"Malucchi","year":"2024","journal-title":"J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/jpm14070692","article-title":"Real-world study of serum Neurofilament light chain levels in Ocrelizumab-treated people with relapsing multiple sclerosis","volume":"14","author":"Barrero Hernandez","year":"2024","journal-title":"J Pers Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1177\/1352458519881428","article-title":"Serum Neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study","volume":"26","author":"Jakimovski","year":"2020","journal-title":"Mult Scler"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/jnnp-2021-328568","article-title":"Serum Neurofilament as a predictor of 10-year Grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study","volume":"93","author":"Lie","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.638","article-title":"Neurofilament light chain serum levels correlate with 10-year Mri outcomes in multiple sclerosis","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum Neurofilament light chain levels in patients with Presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/biomedicines8090312","article-title":"Longitudinal serum Neurofilament levels of multiple sclerosis patients before and after treatment with first-line immunomodulatory therapies","volume":"8","author":"Huss","year":"2020","journal-title":"Biomedicines"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum Neurofilament assessment in Ms","volume":"6","author":"Akgun","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum Neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult Scler"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1177\/1352458518794308","article-title":"Prognostic value of cerebrospinal fluid Neurofilament light chain and Chitinase-3-Like-1 in newly diagnosed patients with multiple sclerosis","volume":"25","author":"Sellebjerg","year":"2019","journal-title":"Mult Scler"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e2457","DOI":"10.1212\/WNL.0000000000009571","article-title":"Plasma Neurofilament light levels are associated with risk of disability in multiple sclerosis","volume":"94","author":"Manouchehrinia","year":"2020","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum Neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1177\/13524585241237388","article-title":"Serum Neurofilament light for detecting disease activity in individual patients in multiple sclerosis: a 48-week prospective single-center study","volume":"30","author":"Johnsson","year":"2024","journal-title":"Mult Scler"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/13524585241277044","article-title":"Impact of serum Neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic","volume":"30","author":"van Lierop","year":"2024","journal-title":"Mult Scler"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1354431","DOI":"10.3389\/fneur.2024.1354431","article-title":"Predictive value of individual serum Neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis","volume":"15","author":"Solis-Tarazona","year":"2024","journal-title":"Front Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"103090","DOI":"10.1016\/j.msard.2021.103090","article-title":"Serum Neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice","volume":"54","author":"Valentino","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum Neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"19982","DOI":"10.1038\/s41598-020-77098-8","article-title":"Serum Neurofilament light chain withstands delayed freezing and repeated thawing","volume":"10","author":"Altmann","year":"2020","journal-title":"Sci Rep"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and Meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/1354750X.2023.2172211","article-title":"Serum Neurofilament light chain in functionally relevant coronary artery disease and adverse cardiovascular outcomes","volume":"28","author":"Amrein","year":"2023","journal-title":"Biomarkers"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","article-title":"Renal function is associated with blood Neurofilament light chain level in older adults","volume":"10","author":"Akamine","year":"2020","journal-title":"Sci Rep"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12889-024-17811-8","article-title":"Correlation analysis between smoke exposure and serum Neurofilament light chain in adults: a Cross-sectional study","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Public Health"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2055217320936318","DOI":"10.1177\/2055217320936318","article-title":"Supplementary medication in multiple sclerosis: real-world experience and potential interference with Neurofilament light chain measurement","volume":"6","author":"Pape","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref60","year":"2019"},{"key":"ref61","volume-title":"CLSI EP07. Interference testing in clinical chemistry","author":"McEnroe","year":"2021"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1212\/WNL.0000000000004411","article-title":"Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis","volume":"89","author":"Rossi","year":"2017","journal-title":"Neurology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/brainsci12121595","article-title":"Real-life experience of the effects of Cladribine tablets on lymphocyte subsets and serum Neurofilament light chain levels in relapsing multiple sclerosis patients","volume":"12","author":"Paolicelli","year":"2022","journal-title":"Brain Sci"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"123070","DOI":"10.1016\/j.jns.2024.123070","article-title":"Clinical and biological predictors of Cladribine effectiveness in multiple sclerosis: a real-world, single Centre study considering a two-year interval from Year-2 dosing","volume":"462","author":"Manni","year":"2024","journal-title":"J Neurol Sci"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/13524585211032348","article-title":"Sustained reduction of serum Neurofilament light chain over 7 years by Alemtuzumab in early relapsing-remitting Ms","volume":"28","author":"Kuhle","year":"2022","journal-title":"Mult Scler"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DNND.S203406","article-title":"Updated perspectives on the challenges of managing multiple sclerosis during pregnancy","volume":"12","author":"Villaverde-Gonzalez","year":"2022","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1212\/WNL.0000000000005065","article-title":"Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era","volume":"90","author":"Alroughani","year":"2018","journal-title":"Neurology"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/HYPERTENSIONAHA.117.10314","article-title":"Neurofilament as neuronal injury blood marker in preeclampsia","volume":"71","author":"Evers","year":"2018","journal-title":"Hypertension"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/ene.13965","article-title":"Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study","volume":"26","author":"Cuello","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","article-title":"Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies","volume":"14","author":"Williamson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"104893","DOI":"10.1016\/j.msard.2023.104893","article-title":"Serum Neurofilaments are a reliable biomarker to early detect Pml in multiple sclerosis patients","volume":"77","author":"Valentino","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1177\/13524585241291452","article-title":"Using serum neurofilament-light in clinical practice: growing enthusiasm that may need bridling","volume":"30","author":"Lycke","year":"2024","journal-title":"Mult Scler"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1571605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T11:54:39Z","timestamp":1743162879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1571605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":73,"alternative-id":["10.3389\/fneur.2025.1571605"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1571605","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1571605"}}